Differential Effects of DX-9065a,Argatroban,and Synthetic Pentasaccharide on Tissue Thromboplastin Inhibition Test and Dilute Russell's Viper Venom Test

Abstract

New synthetic direct and indirect factor Xa or factor Ila inhibitors are increasingly used for the prevention and treatment of thrombotic disorders, including patients suffering from antiphospholipid syndrome. In this study, the effects of the synthetic direct factor Xa inhibitor DX-9065a, the indirect synthetic heparinomimetic pentasaccharide, and the direct factor IIa inhibitor Argatroban were studied. These two widely used assays for the detection of lupus anticoagulant, namely the tissue thromboplastin inhibition (TTIT) and the dilute Russell viper venom tests (DRVVT) proved useful. The drugs were added to a normal human plasma pool ranging in concentration from 0.04 to 10 Ag/mL. Using the two tests named above, DX-9065a and Argatroban showed a dose-related prolongation of TTIT and DRVVT in the concentration range from 0.04 to 5 Amol/mL, but the pentasaccharide only slightly prolonged the clotting times of these assays even at high concentrations. Argatroban had the more pronounced effect on both tests when compared with DX-9065a (p<0.001). The most responsive assay for DX-9065a up to a concentration of 2.5 Amol/mL was the DRVVT. For Argatroban both TTIT and DRVVT were equally responsive. Patients whose plasma was tested for suspected lupus anticoagulant and who have been given DX-9065a or Argatroban may have false-positive results with the TTIT tests and DRVVT. This effect should be considered during patient management. These results indicate that these assays could be used for the effective quantitation of the direct factor Xa or factor Ila inhibitors when suitable controls are used.

Keywords

Lupus anticoagulant Tissue thromboplastin inhibition test Dilute Russell's viper venm test Factor Xa inhibitor Factor IIa inhibitor

References

1. Fareed J , Walenga JM , Hoppensteadt DA , et al. Factor Xa inhibitors in the control of thrombogenesis. Hamostaseologie 1999;19:55-55.

2. Weitz JI , Hirsh J. New antithrombotic agents. Chest 1998;114:715S-715S.

3. Herbert JM , Bernat A , Dol F. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther 1997;276:1030-1030.

4. Hauptmann J , Kaiser B , Nowak G , et al. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990;63:220-220.

5. Kaiser B. Factor Xa versus hIa inhibitors. Clin Appl Thromb Hemost 1997;3(1):16-16.

6. Kaiser B , Jeske W , Walenga JM , et al. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coag Fibrinol 1999;10:495-495.

7. Kaiser B , Callas D , Walenga JM , et al. Synthetic and recombinant antithrombin drugs. Exp Opin Invest Drugs 1998;7(6):963-963.

8. Herbert JM , Petitou M , Lormeau JC , et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15 (1):1-1.

9. Schleider MA , Nachman RL , Jaffe EA . A clinical study of the lupus anticoagulant. Blood 1976;48:499-499.

10.

10. Arnout J , Vanrusselt M , Huybrechts E , et al. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994;87:94-94.

11.

11. Thiagarajan P , Pengo V , Shapiro SS . The use of dilute Russell's viper venom time for the diagnosis of lupus anticoagulant. Blood 1986;68:869-869.

12.

12. Arnout J. Antiphospholipid syndrome: Diagnostics aspects of lupus anticoagulants. Thromb Haemost 2001;86:83-83.

13.

13. Brandt JT , Triplett DA , Alving B , et al. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995;74:1185-1185.

14.

14. Gerbutavicius R , Iqbal O , Messmore HL , et al. Differential effects of unfractioned heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test. Clin Appl Thromb Hemost 2000;6(4):190-190.

15.

15. Walenga JM , Jeske WP , Bara L , et al. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997;86:1-1.

16.

16. Boneu B , Necciari J , Cariou R , et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107A/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-1468.